Status:
COMPLETED
Study of LY2140023 in Schizophrenia Comparing LY2140023, Olanzapine, and Placebo
Lead Sponsor:
Denovo Biopharma LLC
Conditions:
Schizophrenia
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
Brief Summary
Assess the efficacy of a new drug (a receptor agonist that modulates the glutamatergic activity) in the treatment of schizophrenia. The primary objective of this study is to determine if a mGlu2/3 ag...
Detailed Description
The primary objective of this study was to determine if LY2140023 dosed at 40 mg twice daily (BID) for 28 days was superior to placebo in the treatment of patients with schizophrenia as measured by th...
Eligibility Criteria
Inclusion
- meet the DSM-IV criteria for schizophrenia as confirmed by modified SCID
Exclusion
- meet the full syndromal criteria for other Axis I disorder
- have taken any depot antipsychotic within 4 weeks before screening
- are taking mood-stabilizing agents
Key Trial Info
Start Date :
August 23 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 17 2006
Estimated Enrollment :
195 Patients enrolled
Trial Details
Trial ID
NCT00149292
Start Date
August 23 2005
End Date
July 17 2006
Last Update
August 20 2021
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Moscow, Russia
2
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Village Nikolskoe, Russia